Japan's day, wrapped and delivered by morning.
Latest Tokyo Brief coverage on CHUGAI PHARMACEUTICAL CO., LTD., tracking filings, financial news, and market signals from Japan.
TSE:4519
Overseas shipments to majority owner Roche and royalty income from a licensed itch drug pushed Chugai's core profit up 23% in the first half, even as Japan's drug-price cuts dented older cancer medicines at home.
Hemlibra shipments to majority owner Roche and a sharp jump in Nemluvio exports to Galderma drove Chugai's core operating profit up 21% in the first half, while Japan's price controls kept domestic growth modest and management left its full-year guidance exactly where it stood in January.